UK-based GlaxoSmithKline (GSK) and US-based Innoviva have reported positive results from the Phase III clinical trial of Relvar Ellipta to treat patients with asthma.

Relvar Ellipta is a once-daily combination of an inhaled corticosteroid known as fluticasone furoate and a long-acting beta2-agonist vilanterol in a single inhaler, Ellipta.

The results showed that patients treated with Relvar Ellipta achieved better asthma control at week 24 when compared to those receiving standard of care treatments such as inhaled corticosteroids (ICS) or ICS in combination with a long-acting beta agonist (LABA).

Similar statistically significant improvement was observed at weeks 12, 40 and 52.

The multi-centre, open label randomised controlled Phase III trial known as salford lung study (SLS) evaluated 100mcg / 25mcg or 200mcg / 25mcg of Relvar Ellipta in 4,233 patients over 52 weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients received the doses from their own general practitioner in everyday clinical practice.

GSK global respiratory franchise senior vice-president and head Eric Dube said: "The primary endpoint of this study showed that patients initiated with Relvar Ellipta treatment had double the odds of achieving an improvement in asthma control compared with patients continuing usual care in this study in everyday clinical practice.

"Relvar Ellipta is a once-daily combination of an inhaled corticosteroid known as fluticasone furoate and a long-acting beta2-agonist vilanterol in a single inhaler, Ellipta."

"This study has been a tremendous partnership effort between healthcare professionals, patients, academics and GSK and we would like to thank everyone who has helped to make this unique study possible.”

The main objective of the trial was to determine the effectiveness and safety profile of Relvar Ellipta compared to usual asthma maintenance therapy.

The incidence of serious adverse events (SAE) was found to be the same in both cases.

Previously, Relvar Ellipta also demonstrated a positive outcome in a clinical trial conducted for the treatment of patients with chronic obstructive pulmonary disease.

Image: Histopathology of asthma. Photo: courtesy of Yale Rosen/flickr.